Navina vs Reveleer (2026)
The prospective against the retrospective answer to the same contract, and most organisations under risk need both. Navina works inside the visit, surfacing suspected conditions with evidence attached so the clinician documents while the patient is in front of them. Reveleer works after it, retrieving records, parsing charts and populating risk adjustment and quality submissions, which is the machinery that closes a year once the visits are gone. The difference in cost and posture is real: prospective work improves the encounter and the documentation together, retrospective work recovers what the encounter missed and looks more like an audit than like care. Both vendors have the same unanswered question, which is what proportion of the conditions they surface a clinician confirms, and whether either flags codes that should come off as readily as codes that should go on.
- Prospective rather than retrospective. Conditions are surfaced to the clinician during the encounter with evidence attached, so documentation happens while the patient is present rather than through a chart chase afterwards.
- Proprietary language models classify documents and extract structure from free text across the record, exchanges and claims, which is a broader input set than record retrieval alone.
- Named and typed certifications, ISO 27001 and SOC 2 Type II with the type stated, plus native bidirectional integration in workflow.
- Retrospective completeness is a different job and this platform is built for it, automating record retrieval, parsing charts and populating both risk adjustment and quality submissions.
- Retrieval is the hard part of retrospective work and it owns that step rather than assuming the charts arrive, which is what determines whether a submission is complete.
- Quality reporting sits alongside risk adjustment in the same platform, so one workflow serves two regulatory obligations rather than two vendors serving one each.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Navina and Reveleer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Navina | Reveleer |
|---|---|---|
| Primary category | Clinical Decision Support | Value Based Care Intelligence |
| Founded | 2018 | 2009 |
| Headquarters | New York, New York, United States | Glendale, California, United States |
| Website | navina.ai | reveleer.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Navina its top capability grade on AI Centrality, Autonomy and Oversight Model and EHR and Interoperability Depth. Set against Reveleer, Navina grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Reveleer on any axis it scores. Set against Navina, Reveleer grades higher on FDA and Regulatory Status. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Navina or Reveleer?
On the axes where the AI Health Index separates them, Navina grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency, and Reveleer grades higher on FDA and Regulatory Status. Navina leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Navina and Reveleer differ most?
The widest separation the AI Health Index records between Navina and Reveleer is on EHR and Interoperability Depth, where Navina grades A and Reveleer grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do Navina and Reveleer grade the same?
The AI Health Index grades Navina and Reveleer the same on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Navina and Reveleer not disclosed?
At the last review, at least one of Navina and Reveleer published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Autonomous Medical Coding page.
Prospective and retrospective risk adjustment are complementary and most risk bearing organisations run both, so treat this as a sequencing question rather than a choice. The governance issue is the same on both sides and neither addresses it: a platform that surfaces more diagnoses raises risk adjusted revenue whether or not the patient is sicker, and neither vendor publishes a confirmation rate, an add to delete ratio, or evidence that it flags codes lacking documentation for removal as readily as it suggests additions. Ask both for the two way number. Neither publishes pricing.